Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
EXCEED-ET Investigates an Alternative Option for Disease Modification in Essential Thrombocytopenia
July 16th 2023In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.
Read More
Biomarker Analysis Shows Better Outcomes for Undetectable ctDNA in GIST
July 6th 2023Jonathan C. Trent, MD, PhD, discusses the molecular analyses of the INTRIGUE study, which was supported by Caris Life Science’s Precision Oncology Alliance, investigating patients with GIST that were presented at ASCO 2023.
Watch
Treatment for EGFR-Mutant NSCLC Varies by Driver
June 30th 2023In an interview with Targeted Oncology, Nicholas Girard, MD, PhD reviews 3 key abstracts presented at the ELCC 2023, in which different targeted therapies were administered to patients with EGFR-mutant non–small cell lung cancer in clinical trial and real-world settings.
Read More
MET Overexpression as a Predictive Biomarker in Post-Osimertinib NSCLC
June 26th 2023In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Read More